A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Copper-gluconate/disulfiram (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Cantex Pharmaceuticals
- 31 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Nov 2018.
- 31 Jul 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Sep 2018.
- 31 Jul 2018 Status changed from recruiting to active, no longer recruiting.